The integration of
oncolytic viruses (OVs) with
immunotherapy is reshaping the landscape of
tumor treatment, offering new hope for patients. This cutting-edge approach harnesses the ability of OVs to selectively
infect and destroy tumor cells, while simultaneously stimulating
anti-tumor immune responses. The latest advancements in
genetic engineering have further optimized these therapies, leading to improved clinical outcomes and enhanced
patient quality of life.
By combining OVs with
cellular immunotherapy, immune checkpoint inhibitors, cancer vaccines, cytokines, and
bi- or tri-specific T cell engagers, researchers have developed innovative strategies that
overcome the limitations of OV monotherapy. These synergistic treatments amplify the body’s natural defenses, creating a powerful
dual attack against cancer cells while minimizing adverse effects.
One of the key breakthroughs in this field has been the ability to
genetically modify OVs to enhance their tumor-targeting efficiency. Modified viruses can express
immune-stimulating molecules, improving their ability to
recruit and activate immune cells within the tumor microenvironment. This has led to
remarkable improvements in tumor eradication, particularly in difficult-to-treat cancers.
The potential of OV-based combination therapies extends across multiple cancer types, including
solid tumors, where conventional treatments often fall short. With
ongoing clinical trials and continued research into the underlying
anti-tumor mechanisms, these therapies are expected to become a
cornerstone of next-generation cancer treatment.
As the field of
precision medicine continues to evolve, oncolytic virus-based
combination immunotherapy is emerging as a promising and effective strategy for patients worldwide. With its ability to
enhance immune activation, improve treatment efficacy, and reduce toxicity, this novel approach represents a significant step forward in the fight against cancer.
# # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.
Scopus CiteScore: 8.4
Impact Factor: 9.4
# # # # # #
More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available
online in
ScienceDirect (
https://www.sciencedirect.com/journal/genes-and-diseases ).
Submissions to
Genes & Disease may be made using
Editorial Manager (
https://www.editorialmanager.com/gendis/default.aspx ).
Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R
Contact Us: editor@genesndiseases.com
X (formerly Twitter): @GenesNDiseases (
https://x.com/GenesNDiseases )
# # # # # #
Reference
Xiaoli Zhou, Shunfeng Hu, Xin Wang, Recent advances in oncolytic virus combined immunotherapy in tumor treatment, Genes & Diseases, Volume 12, Issue 6, 2025, 101599,
https://doi.org/10.1016/j.gendis.2025.101599
Funding Information:
National Natural Science Foundation of China 82270200
National Natural Science Foundation of China 82070203
National Natural Science Foundation of China 81770210
National Natural Science Foundation of China 82400231
Taishan Scholars Program of Shandong Province, China; Shandong Provincial Engineering Research Center of Lymphoma (China); Key Research and Development Program of Shandong Province, China (No. 2018CXGC1213)
Academic Promotion Programme of Shandong First Medical University (China) 2019QL018
Translational Research Grant of the National Clinical Research Center for Hematologic Diseases (NCRCH) (China) 2021WWB02
Translational Research Grant of the National Clinical Research Center for Hematologic Diseases (NCRCH) (China) 2020ZKMB01
China Postdoctoral Science Foundation 2023M741506
Shandong Provincial Natural Science Foundation (China) ZR2023QH193